HanAll Biopharma Reports Q3 Revenue of 40.8 Billion KRW, Up 10.8% Year-on-Year

On October 29, HanAll Biopharma announced its provisional consolidated financial results for the third quarter of this year. The company reported third-quarter revenue of 40.8 billion KRW, marking a 10.8% increase compared to the same period last year. Operating profit stood at 350 million KRW, and net profit reached 300 million KRW. Cumulative revenue for the year was 117.6 billion KRW, representing a 14.7% increase compared to the same period last year.

Pharmaceutical sales in the third quarter reached 35.5 billion KRW, an 11.5% year-on-year increase, maintaining double-digit growth. In particular, the probiotic pharmaceutical ‘Biotop’ strengthened its brand influence by ranking first in the Ubist prescription market for microbial antidiarrheal agents in August. Additionally, the prostate cancer and precocious puberty treatment ‘Eligard’ achieved 10 billion KRW in sales earlier than expected, bringing the company closer to reaching the 20 billion KRW ‘mega-brand’ milestone together with Biotop. The hair loss treatment ‘Hairgrow’ recorded its highest-ever monthly sales in September, with 2.5 million tablets sold, and maintained a solid number one position in the finasteride 1mg generic prescription market.

Meanwhile, HanAll Biopharma further solidified its foundation for sustainable growth by successfully renewing its ISO 37001 international standard anti-bribery management system certification.

The research and development sector also made meaningful progress. The autoimmune disease treatment ‘Batoclimab (HL161BKN)’ demonstrated the potential to become a fundamental therapy for patients unresponsive to existing treatments, based on six-month maintenance effect data following the discontinuation of phase 2 clinical treatment for Graves’ disease (GD) in September. Clinical results showed that about 80% of patients maintained normal thyroid hormone levels for six months after stopping Batoclimab treatment, with half of them remaining stable even without antithyroid drugs. In the fourth quarter, results from the phase 3 clinical trial for thyroid eye disease (TED) are expected to be secured.

Research and development for ‘Imerofrubat (HL161ANS),’ a next-generation FcRn therapeutic, is also proceeding as planned. Based on clinical data from Batoclimab, Imerofrubat is being developed for a total of six autoimmune diseases: myasthenia gravis (MG), Graves’ disease (GD), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjogren's syndrome (SjD), and cutaneous lupus erythematosus (CLE).

The clinical trial for the dry eye disease treatment ‘Tanfanercept’ is underway, targeting topline results in 2026, while the Parkinson’s disease treatment ‘HL192’ is also aiming to enter the next clinical phase in 2026. Additionally, the company continues research on an mRNA lipid nanoparticle (LNP)-based rejuvenation therapy introduced last year, further strengthening its immunology-based research and development capabilities.

Jung Seungwon, CEO of HanAll Biopharma, stated, “The third quarter was a meaningful period where progress in innovative new drug clinical trials and solid pharmaceutical sales enabled us to strengthen our fundamentals. We will continue to do our utmost to generate sustainable results and maximize the value of our current pipeline under development.”